Skip to main content

Table 1 Baseline characteristics of the study population

From: HAART, DOTS and renal disease of patients co-infected with HIV/AIDS and TB in the South West Region of Cameroon

   Frequency no (%)
Study Area Buea 87 (43.5 %)
  Limbe 62 (31.0)
  Kumba 51 (25.5)
  Total 200 (100)
Gender Male 101 (50.5)
  Female 99 (49.5)
  Total 200 (100)
Age group (years) mean = 38.04 ± 10.52 years   
  21–30 55 (27.5)
  31–40 76 (38.0)
  41–50 43 (21.5)
  ≥51 26 (13.0)
  Total 200 (100)
Education level No formal education 12 (6.0)
  Primary 87 (43.5)
  Secondary 74 (37.0)
  Tertiary 27 (13.0)
  Total 200 (100)
eGFR (ml/min/1.73 m2) <60 16 (8.0)
  ≥60 184 (92.0)
  Total 200 (100)
Treatment groups HAART 70 (35.0)
  DOTS 70 (35.0)
  HAART/ DOTS 60 (30.0)
  Total 200 (100)
Type of HAART AZT/3TC/NVP 46 (65.7)
1 HAART group (n = 70) AZT/3TC/EVP 3 (4.3)
TNV/3TC/NVP 21 (30.0)
2 HAART/DOTS group (n = 60) AZT/3TC/NVP 34 (56.7)
  AZT/3TC/EVP 3 (5.0)
  TNV/3TC/NVP 23 (38.3)
  Total 130 (65)
Type of DOTS   
1 DOTS group (n = 70)   
  RIF/INH/ETH/PZA 38 (54.3)
  RIF/INH 32 (45.7)
2 HAART/DOTS group (n = 60) RIF/INH/ETH/PZA 25 (41.7)
  RIF/INH 35 (58.3)
  Total 130 (65)
  1. Key: AZT/3TC/NVP Zidovudine, Lamivudine, Nevirapine, AZT/3TC/EFV Zidovudine, Lamivudine, Efavirenz, TDF/3TC/EFV Tenofovir, Lamivudine, Efavirenz, HAART Highly Active Antiretroviral Therapy, DOTS Direct Observed Therapy, Short-course, RIF/INH/ETH/PZA rifamycin, isoniazid, ethambutol, pyrazinamide, RIF/INH rifamycin, isoniazid